Scroll Back to Top


CPT For CPT coding, call 800-222-7566, ext. 6-8400

Test Details

Cancer Type

Acute lymphocytic leukemia (ALL), Hematologic malignancies, Leukemia

Technology Used


Turnaround Time

2 days


B-ALL MRD testing has two parts based on COG consensus and is approved by COG. 1) a 5-antibody panel for blood sample from patients on day 8 of induction, and 2) a 12-antibody panel for bone marrow sample from patients on day 29 of induction. This 12-antibody panel is suitable for all MRD monitoring on bone marrow specimen from either pediatric or adult patients.  The test uses a sequential gating strategy to isolate leukemic cells from normal mature and immature B-cells in the background. The test detects 1 B-ALL cell in 10,000 normal B-cells (0.01%). It provides a quantitative measurement of the MRD status and a trending graph in the report. Patients who achieve MRD-negative status have improved overall and progression-free survival. This test is not suitable for making primary diagnosis of B-ALL.


There must be a minimum of 5 million cells in the specimen submitted to perform the test (10 million cells preferred).


Flow Cytometry

Specimen Requirements

Information on collection, storage, and volume


Whole blood or bone marrow


10 mL whole blood; 2 mL bone marrow aspirate


Green-top (sodium heparin) tube (preferred) or lavender-top (EDTA)

Storage Instructions

Maintain specimen at room temperature.

Causes for Rejection

Hemolysis; specimen clotted; specimen frozen; specimen in formalin or other fixative; blood more than 72 hours old; bone marrow aspirates more than five days old; bags or bottles of body fluid or bronchial washing; tissue in formalin or other fixative; contaminated transport medium


All specimens should be shipped to Labcorp Oncology on the day of excision. Delay in shipping may compromise cell viability and results.